



# Source details

## BMJ Open

Open Access ⓘ

Scopus coverage years: from 2011 to Present

Publisher: BMJ Publishing Group

ISSN: 2044-6055

Subject area: Medicine: General Medicine

Source type: Journal

CiteScore 2021

3.9 ⓘ

SJR 2021

0.982 ⓘ

SNIP 2021

1.294 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology ⓘ

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▾

$$3.9 = \frac{57,646 \text{ Citations 2018 - 2021}}{14,598 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$3.8 = \frac{61,331 \text{ Citations to date}}{15,940 \text{ Documents to date}}$$

Last updated on 05 October, 2022 • Updated monthly

## CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
General Medicine	#154/826	81st

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

- Home
- Journal Rankings
- Country Rankings
- Viz Tools
- Help
- About Us



### Intl. J of Distrib. Sens. Net

Submit Your Paper to the International Journal of Distriil Sensor Networks, OA Journal

Hindawi

## BMJ Open

#### COUNTRY

United Kingdom



Universities and research institutions in United Kingdom

#### SUBJECT AREA AND CATEGORY

Medicine  
Medicine (miscellaneous)

#### PUBLISHER

BMJ Publishing Group



BMJ Group in Scimago Institutions Rankings

#### H-INDEX

# 121

#### PUBLICATION TYPE

Journals

#### ISSN

20446055

#### COVERAGE

2011-2021

#### INFORMATION

- [Homepage](#)
- [How to publish in this journal](#)
- [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)


## Journal Cover Letter Templates

Open



Microsoft 365

epidemiology. We also welcome studies in health services research, health economics, surgery, quantitative research, research methods, medical education, medical publishing and any other field that directly addresses patient outcomes or the practice and delivery of healthcare. Our focus is on research that is relevant to patients and clinicians. We do not publish studies conducted in animals, laboratory studies not linked to patient outcomes, papers reporting solely physiological or biomechanical results from healthy participants, anatomy, cell biology or non-clinical psychology. All research study types are considered, from study protocols through phase I trials to meta-analyses. This includes specialist studies and studies reporting negative results.

 Join the conversation about this journal



---

## Intl. J of Distrib. Sens. Net

Submit Your Paper to the International Journal of Distributed Sensor Networks, OA Journal

Hindawi

---

 Quartiles  


---

## Intl. J of Distrib. Sens. Net

Submit Your Paper to the International Journal of Distributed Sensor Networks, OA Journal









Hindawi

---

### FIND SIMILAR JOURNALS

<p>1 <b>Trials</b> GBR</p>	<p>2 <b>Chinese Journal of Evidence-Based Medicine</b> CHN</p>	<p>3 <b>BMC Medicine</b> GBR</p>	<p>4 <b>Health Tech Assessment</b> GBR</p>
------------------------------------	--	--	--





**BMJ Open**

Q1  
Medicine (miscellaneous)  
best quartile

SJR 2021  
0.98

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" data-bbox="635 835 780 855">
```



Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Metrics based on Scopus® data as of April 2022

L **Luis Armando** 3 years ago

Buenas tardes soy el Dr. Ríos Valdepeña, soy residente en Medicina del Trabajo y Ambiental y estoy interesado en realizar una publicación en su revista, pero quisiera saber el costo para este fin.

Que tenga un excelente tarde.....

reply

SCImago Team

E **Estefania Herran Paez** 3 years ago

Estimado Doctor Ríos:  
Gracias por escribirnos.

Lamentamos informarle que SCImago Journal & Country Rank no es una revista. SJR es un portal con indicadores cuantitativos de revistas indexadas en Elsevier / Scopus razón por la cual, desafortunadamente, no podemos ayudarle con su solicitud. Le sugerimos visitar el sitio web de la revista (específicamente información para autores) o que comunicarse con el personal editorial de la revista, para que puedan informarle correctamente.

Saludos cordiales,  
Equipo SCImago



Email

(will not be published)

I'm not a robot reCAPTCHA  
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS  
Horatio (Satire 1,1,106)

[Edit Cookie Consent](#)



Microsoft 365

BMJ Open is an online, open access journal, dedicated to publishing medical research from all disciplines and therapeutic areas.

**Impact Factor:** 3.006

**Citescore:** 3.9

[All metrics >>](#)

Current Issue



Authors

Author information

Submit a paper

Press Releases





Home / Table of contents

## Table of contents

[← Prev issue](#)

[Next issue →](#)

### November 2020 - Volume 10 - 11

Original research: Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation (18 November, 2020)

Holly Knight, David Harman, Joanne R Morling, Guruprasad Aithal, Timothy Card, Indra Neil Guha, Manpreet Bains

Protocol: Predicting treatment outcomes for bilinguals with aphasia using computational modeling: Study protocol for the PROCoM randomised controlled trial (18 November, 2020)

Claudia Peñaloza, Maria Dekhtyar, Michael Scimeca, Erin Carpenter, Nishaat Mukadam, Swathi Kiran

Original research: Prospective association between social engagement and cognitive impairment among middle-aged and older adults: evidence from the China Health and Retirement Longitudinal Study (18 November, 2020)

Shuduo Zhou, Suhang Song, Yinzi Jin, Zhi-Jie Zheng

Protocol: Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam—hepatitis C) (18 November, 2020)

Delphine Rapoud, Catherine Quillet, Khue Pham Minh, Vinh Vu Hai, Binh Nguyen Thanh, Thanh Nham Thi Tuyet, Hong Tran Thi, Jean-Pierre Molès, Roselyne Vallo, Laurent Michel, Jonathan Feelemyer, Laurence Weiss, Maud Lemoine, Peter Vickerman, Hannah Fraser, Huong Duong Thi, Oanh Khuat Thi Hai, Don Des Jarlais, Nicolas Nagot, Didier Laureillard

Original research: Health professionals' perceptions of weight loss programmes and recommendations for future implementation: a qualitative study (18 November, 2020)

Christina Jessen-Winge, Pia Marie Ilvig, Trine Thilsing, Kim Lee, Heather Fritz, Jeanette Refstrup Christensen

Original research: Challenges, experience and coping of health professionals in delivering healthcare in an urban slum in India during the first 40 days of COVID-19 crisis: a mixed method study (18 November, 2020)

Carolin Elizabeth George, Leeberk Raja Inbaraj, Shon Rajukutty, Luc P de Witte

Original research: Evaluation of a wearable wireless device with artificial intelligence, iThermonitor WT705, for continuous temperature monitoring for patients in surgical wards: a prospective comparative study (18 November, 2020)


Yuwei Liu, Changqing Liu, Min Gao, Yan Wang, Yangjing Bai, Ruihua Xu, Renrong Gong

Protocol: Biofortification of wheat with zinc for eliminating deficiency in Pakistan: study protocol for a cluster-randomised, double-blind, controlled effectiveness study (BIZIFED2) (18 November, 2020)

Nicola M Lowe, Mukhtiar Zaman, Victoria Hall Moran, Heather Ohly, Jonathan Sinclair, Sadia Fatima, Martin R Broadley, Edward J M Joy, Usman Mahboob, R Murray Lark, Munir H Zia, E Louise Ander, Paul A Sharp, Elizabeth H Bailey, Scott D Young, Muhammad Jaffar Khan

Original research: Changes in public preferences for technologically enhanced surveillance following the COVID-19 pandemic: a discrete choice experiment (18 November, 2020)


Chris Degeling, Gang Chen, Gwendolyn L Gilbert, Victoria Brookes, Thi Thai, Andrew Wilson, Jane Johnson

Original research: Caesarean section and the association with migraine: a retrospective register-linked HUNT population cohort study (18 November, 2020) 


Espen Saxhaug Kristoffersen, Sigrid Børte, Knut Hagen, John-Anker Zwart, Bendik Slagsvold Winsvold

Original research: Occurrence, mortality and cost of brain disorders in Denmark: a population-based cohort study (17 November, 2020) 


Søren Viborg Vestergaard, Thomas Bøjer Rasmussen, Sandra Stallknecht, Jens Olsen, Niels Skipper, Henrik Toft Sørensen, Christian Fynbo Christiansen

Original research: Disease composition and epidemiological characteristics of primary care visits in Pudong New Area, Shanghai: a longitudinal study, 2016–2018 (17 November, 2020) 


Xin Gong, Xiaoli Wang, Tianxing Shi, Jianwei Shi, Wenya Yu, Liang Zhou, Ning Chen, Jiaoling Huang, Zhaoxin Wang

Original research: Impact of secondhand smoke exposure on cognitive function among middle-aged and older women in China: findings from three waves of the China Health and Retirement Longitudinal Study (17 November, 2020) 


Anying Bai, Yinzi Jin, Yangmu Huang

Original research: Characteristics and well-being of urban informal home care providers during COVID-19 pandemic: a population-based study (17 November, 2020) 


Emily YY Chan, Eugene SK Lo, Zhe Huang, Jean H Kim, Heidi Hung, Kevin KC Hung, Eliza LY Wong, Samuel YS Wong, Nina Gobat

Original research: Characteristics of online medical care consultation for pregnant women during the COVID-19 outbreak: cross-sectional study (17 November, 2020) 


Miaomiao Chen, Xiyao Liu, Jun Zhang, Guoqiang Sun, Ying Gao, Yuan Shi, Philip Baker, Jing Zeng, Yangxi Zheng, Xin Luo, Hongbo Qi

Protocol: Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial (17 November, 2020) 


Barbara de Barros, Saba M Lambert, Mahesh Shah, Vivek V Pai, Joydeepa Darlong, Benjamin Jewel Rozario, Medhi Denisa Alinda, Anna M Sales, Shimelis Doni, Deanna A Hagge, Dilip Shrestha, M. Yulianto Listiawan, Abeba M Yitaye, Jose A C Nery, Kapil D Neupane, Vivianne L A Dias, C. Ruth Butlin, Peter G Nicholls, Diana Lockwood, Stephen L Walker

Original research: Level of vital and laboratory values on arrival, and increased risk of 7-day mortality among adult patients in the emergency department: a population-based cohort study (17 November, 2020) 


Peter Bank Pedersen, Daniel Pilsgaard Henriksen, Mikkel Brabrand, Annmarie Touborg Lassen

Protocol: Motivational Interviewing for Maternal Immunisation (MI4MI) study: a protocol for an implementation study of a clinician vaccine communication intervention for prenatal care settings (17 November, 2020) 

Sarah E. Brewer, Jessica R. Cataldi, Mary Fisher, Russell E. Glasgow, Kathleen Garrett, Sean T. O'Leary

Original research: Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study (17 November, 2020) 

Alvina G Lai, Laura Pasea, Amitava Banerjee, Geoff Hall, Spiros Denaxas, Wai Hoong Chang, Michail Katsoulis, Bryan Williams, Deenan Pillay, Mahdad Noursadeghi, David Linch, Derralynn Hughes, Martin D Forster, Clare Turnbull, Natalie K Fitzpatrick, Kathryn Boyd, Graham R Foster, Tariq Enver, Vahe Nafilyan, Ben Humberstone, Richard D Neal, Matt Cooper, Monica Jones, Kathy Pritchard-Jones, Richard Sullivan, Charlie Davie, Mark Lawler, Harry Hemingway

Protocol: Efficacy of quadruple regimen with polaprezinc for gastric *Helicobacter pylori* infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial (17 November, 2020) 

Dingkun Wu, Zhen Sun, Tingyuan Li, Qinwen Tan, Yue Sun, Tingting Chen, Yujing Liu, Jun Li, Haidong Jiang, Zhiqiang Yuan, Yuqian Zhao, Wen Chen

---

[Home](#) / Editorial Board

# Editorial Board

---

*BMJ Open* Editorial Board members have agreed and adhere to the [BMJ Editor Roles and Responsibilities guidelines](#); including our Editor policy on [competing interests](#).

---

## Editor in Chief

### Adrian Aldcroft

BMJ

London, UK

 [orcid.org/0000-0003-0106-720X](https://orcid.org/0000-0003-0106-720X)

[Competing Interests](#)

### Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

#### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

#### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)

**Edward Sucksmith**

BMJ

London, UK

 [orcid.org/0000-0003-1419-9359](https://orcid.org/0000-0003-1419-9359)

## Research Editors

**Artur Arikainen**

BMJ

London, UK

 [orcid.org/0000-0001-7836-1197](https://orcid.org/0000-0001-7836-1197)**Neil Bennet**

BMJ

London, UK

 [orcid.org/0000-0002-9342-443X](https://orcid.org/0000-0002-9342-443X)**Amy Branch-Hollis**

BMJ

London, UK

 [orcid.org/0000-0002-9750-8008](https://orcid.org/0000-0002-9750-8008)**Anne Menard**

BMJ

London, UK

### Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**[I Accept](#)[Show Purposes](#)

**Nicole Martin**

BMJ

London, UK

 [orcid.org/0000-0001-9186-1313](https://orcid.org/0000-0001-9186-1313)**Thomas Phillips**

BMJ

London, UK

 [orcid.org/0000-0002-4709-2550](https://orcid.org/0000-0002-4709-2550)

## Editorial Coordinator

**Becky Kitchin**

BMJ

London, UK

## Associate Editors

**Alison Walker**

BMJ

London, UK

**Tiago Villanueva**

### Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**[I Accept](#)[Show Purposes](#)

**Ana Lopez**

BMJ

London, UK

**Helen Surana**

BMJ

London, UK

**Jennifer Thorley**

BMJ

London, UK

**Emma Veitch**

BMJ

London, UK

## Editorial Advisory Board

**Abdullah Aljoudi**

University of Dammam

Al Khobar, Saudi Arabia

**Fredrick Ashbury**

### Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**[I Accept](#)[Show Purposes](#)

**Christina Bergh**

Sahlgrenska University Hospital  
Gothenburg, Sweden

**Jeffrey Braithwaite**

Macquarie University  
Sydney, Australia

**Meredith Brooks**

Boston University  
Boston, USA

**Chris Bullen**

University of Auckland  
Auckland, New Zealand

**Alexandra Burton**

University College London  
London, UK

**Andrew Bush**

Imperial College London  
London, UK

**Christopher Butler****Cookies and privacy**

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**

[I Accept](#)

[Show Purposes](#)

**Rosario Ferrer Cascales**

University of Alicante

Alicante, Spain

**Tsion Firew**

Columbia University

New York, USA

**Joel Francis**

University of the Witwatersrand

Johannesburg, South Africa

**Nicholas Graves**

Queensland University of Technology

Brisbane, Australia

**Lucy Griffiths**

Swansea University,

Swansea, UK

**Gordon Guyatt**

McMaster University

Hamilton, Canada

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)



**Rose Anne Kenny**

Trinity College Dublin  
Dublin, Ireland

**Emma Kirby**

University of New South Wales,  
Sydney, Australia

**Nigel Klein**

Institute of Child Health  
London, UK

**Sallie Lamb**

University of Oxford  
Oxford, UK

**Liliana Laranjo**

Macquarie University  
Sydney, Australia

**Heidi Lempp**

King's College London  
London, UK

**Cookies and privacy**

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**

**I Accept**

**Show Purposes**

Sydney, Australia

**Parker Magin**

The University of Newcastle  
Callaghan, Australia

**Arch G. Mainous III**

University of Florida  
Florida, USA

**Tanja Manser**

University of Applied Sciences and Arts Northwestern Switzerland  
Olten, Switzerland

**Shabir Moosa**

University of the Witwatersrand  
Johannesburg, South Africa

**Irwin Nazareth**

University College London  
London, UK

**Anna Odone**

University of Pavia

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)

Boston University

Boston, USA

**Jane Sandall**

King's College London

London, UK

**Lesley Stewart**

University of York

York, UK

**Stephanie Stock**

University Clinic of Cologne

Cologne, Germany

**Martin Stockler**

University of Sydney

Sydney, Australia

**Lehana Thabane**

McMaster University

Hamilton, Canada

**Matthew Thompson**

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)

**Andrew Vickers**

Memorial Sloan-Kettering Cancer Centre  
New York, USA

**Cecilia Vindrola**

University College London  
London, UK

**Jo Waller**

University College London  
London, UK

**Fiona M. Walter**

University of Cambridge  
Cambridge, UK

**Yize Wan**

Queen Mary University of London  
London, UK

**Hywel Williams**

University of Nottingham  
Nottingham, UK

**Cookies and privacy**

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

**We and our partners process data to provide:**

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

**List of Partners (vendors)**

[I Accept](#)

[Show Purposes](#)

University of York

York, UK

**Peter Baade**

Cancer Council Queensland

Queensland, Australia

**Adrian Barnett**

Queensland University of Technology

Queensland, Australia

**Alan Batterham**

Teesside University

Middlesbrough, UK

**Robin Christensen**

Copenhagen University Hospital

Copenhagen, Denmark

**Stephen-Mark Cooper**

Cardiff Metropolitan University

Cardiff, UK

**Helen Dakin**

University of Oxford

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)

**Lu Kang**

US Food and Drug Administration  
Maryland, USA

**Bernet Kato**

Imperial College London  
London, UK

**Jake Olivier**

University of New South Wales  
Sydney, Australia

**Timothy Pickles**

Cardiff University,  
Cardiff, UK

**Avinesh Pillai**

University of Auckland  
Auckland, New Zealand

**Katie Saunders**

University of Cambridge  
Cambridge, UK

**Yana Vinogradova**

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)

[Show Purposes](#)

**Associate Publisher:** Geetna Balasudramaniam**Publisher:** Theodora Bloom

## CONTENT

[Latest Content](#)[Archive](#)[Browse by collection](#)[Most read articles](#)[Top cited articles](#)[Responses](#)

## JOURNAL

[About](#)[Editorial Board](#)[Sign up for email alerts](#)[Thank you to our reviewers](#)[Top Cited Obstetrics and Gynaecology Articles](#)

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)[Show Purposes](#)

[HELP](#)[Contact us](#)[Reprints](#)[Permissions](#)[Advertising](#)[Feedback form](#)**BMJ**[Website Terms & Conditions](#)[Privacy & Cookies](#)[Contact BMJ](#)[Cookie settings](#)

Online ISSN: 2044-6055

Copyright © 2022 BMJ Publishing Group Ltd. All rights reserved.

## Cookies and privacy

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. **Cookie policy**

### We and our partners process data to provide:




Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

[I Accept](#)[Show Purposes](#)



# BMJ Open Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial

Barbara de Barros <sup>1</sup>, Saba M Lambert <sup>1,2</sup>, Mahesh Shah,<sup>3</sup> Vivek V Pai,<sup>4</sup> Joydeepa Darlong,<sup>5</sup> Benjamin Jewel Rozario,<sup>6</sup> Medhi Denisa Alinda,<sup>7</sup> Anna M Sales,<sup>8</sup> Shimelis Doni,<sup>2</sup> Deanna A Hagge,<sup>3</sup> Dilip Shrestha,<sup>3</sup> M. Yulianto Listiawan,<sup>7</sup> Abeba M Yitaye,<sup>2</sup> Jose A C Nery,<sup>8</sup> Kapil D Neupane,<sup>3</sup> Vivianne L A Dias,<sup>8</sup> C. Ruth Butlin,<sup>6</sup> Peter G Nicholls,<sup>1</sup> Diana Lockwood,<sup>1</sup> Stephen L Walker <sup>1</sup>

**To cite:** de Barros B, Lambert SM, Shah M, *et al.* Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. *BMJ Open* 2020;**10**:e037700. doi:10.1136/bmjopen-2020-037700

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-037700>).

Received 13 February 2020  
Revised 07 October 2020  
Accepted 23 October 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Barbara de Barros;  
[barbara.de-barros@lshtm.ac.uk](mailto:barbara.de-barros@lshtm.ac.uk)

## ABSTRACT

**Introduction** Erythema nodosum leprosum (ENL) is an immunological complication of leprosy. ENL results in morbidity and disability and if it is not treated can lead to death. The current treatment consists of thalidomide or high doses of oral corticosteroids for prolonged periods. Thalidomide is not available in many leprosy endemic countries. The use of corticosteroids is associated with morbidity and mortality. Identifying treatment regimens that reduce the use of corticosteroids in ENL is essential. Methotrexate (MTX) is used to treat many inflammatory diseases and has been used successfully to treat patients with ENL not controlled by other drugs, including prednisolone and thalidomide. We present the protocol of the ‘MTX and prednisolone study in ENL’ (MaPs in ENL) a randomised controlled trial (RCT) designed to test the efficacy of MTX in the management of ENL.

**Methods and analysis** MaPs in ENL is an international multicentre RCT, which will be conducted in leprosy referral centres in Bangladesh, Brazil, Ethiopia, India, Indonesia and Nepal. Patients diagnosed with ENL who consent to participate will be randomly allocated to receive 48 weeks of weekly oral MTX plus 20 weeks of prednisolone or 48 weeks of placebo plus 20 weeks of prednisolone. Participants will be stratified by type of ENL into those with acute ENL and those with chronic and recurrent ENL. The primary objective is to determine whether MTX reduces the requirement for additional prednisolone. Patients’ reported outcome measures will be used to assess the efficacy of MTX. Participants will be closely monitored for adverse events.

**Ethics and dissemination** Results will be submitted for publication in peer-reviewed journals. Ethical approval was obtained from the Observational/Interventions Research Ethics Committee of the London School of Hygiene & Tropical Medicine (15762); The Leprosy Mission International Bangladesh Institutional Research Board (in process); AHRI-ALERT Ethical Review Committee, Ethiopia; Ethics Committee of the Managing Committee of the Bombay Leprosy Project; and The Leprosy Mission Trust India Ethics Committee; the Nepal Health and

## Strengths and limitations of this study

- This is the first randomised controlled trial to evaluate efficacy of methotrexate (MTX) in the management of erythema nodosum leprosum (ENL).
- We will use the Erythema Nodosum Leprosum International Study ENL Severity Scale to evaluate the severity of ENL to ensure consistency of patient recruitment between the study centres.
- Participants will be stratified according to the type of ENL acute or chronic and recurrent.
- Data will be collected on adverse events.
- MTX can cause severe nausea, which may lead to loss of allocation concealment.

Research Council and Health Research Ethics Committee Dr. Soetomo, Indonesia. This study is registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov). This is the first RCT of MTX for ENL and will contribute to the evidence for the management of ENL. Trial registration number NCT 03775460.

## INTRODUCTION

Erythema nodosum leprosum (ENL) is an immunological complication of borderline lepromatous (BL) leprosy and lepromatous leprosy (LL).<sup>1</sup> ENL affects up to 50% of individuals with LL and approximately 5%–10% of patients with BL.<sup>1,2</sup> It is estimated that over 50 000 new patients with leprosy diagnosed each year are at risk developing of ENL,<sup>3</sup> which may occur before, during or after successful completion of multidrug therapy (MDT). The inflammatory state of ENL causes significant morbidity and may be associated with death.<sup>3,4</sup> Having a family member with ENL may produce severe economic hardship.<sup>5</sup>

ENL is a multisystem inflammatory disorder characterised by extensive crops of painful skin lesions, fever, arthralgia, arthritis, osteitis, dactylitis, lymphadenitis, iritis, orchitis and neuritis. When severe, lesions may ulcerate. ENL is often chronic requiring treatment for several years.<sup>1</sup>

The histology of ENL skin lesions classically shows an intense perivascular infiltrate of neutrophils throughout the dermis and subcutis.<sup>6</sup> There is evidence of neutrophils and immune complexes playing a role in the inflammation associated with ENL, yet it is uncertain whether they initiate the process.<sup>7</sup> There is also evidence of T lymphocyte and macrophage activation and expression of mRNA for Tumor Necrosis Factor- $\alpha$  (TNF $\alpha$ ) and IL-12 in the skin.<sup>8</sup> Several studies have shown increased levels of TNF $\alpha$ , IL-6, IL-12 and IL-17, in skin and blood.<sup>7,9,10</sup>

Patients with ENL are treated with corticosteroids and/or thalidomide, which are used for prolonged periods of months or even years.<sup>4</sup> Thalidomide is effective for many individuals with ENL but is not readily available in many countries because of its teratogenic effects.<sup>11,12</sup> Thalidomide is also associated with adverse effects such as somnolence, nausea, neurotoxicity, dizziness and thromboembolism, which may limit its use.<sup>13</sup> Many patients require prolonged, high doses of corticosteroids to control their inflammation that are associated with morbidity and in some settings death.<sup>3</sup>

The identification of other agents for controlling ENL is a priority.<sup>14</sup> Since the introduction of MDT, there have been eight randomised controlled trials (RCTs) of potential treatments for ENL, involving just 369 (median 22 (range 10–100)) individuals and all had significant methodological limitations including lack of standardisation, allocation concealment and non-validated outcome measures.<sup>15–22</sup>

### Rationale for using methotrexate

Methotrexate (MTX) is an immunosuppressant agent used in the treatment of malignant and inflammatory diseases.<sup>23,24</sup> MTX was first introduced in 1948 to treat acute leukaemia and in 1951, Gubner published his findings on the rapid improvement of psoriasis in patients being treated with aminopterin, an unstable precursor of MTX.<sup>25</sup> Low doses of oral MTX are widely used in paediatric and adult care to manage TNF- $\alpha$ -driven autoimmune and inflammatory diseases including psoriasis, inflammatory spondylo-arthritis, vasculitis and inflammatory bowel disease, in doses between 7.5 mg and 25 mg once a week.<sup>26</sup> MTX is included in the WHO model list of essential medicines.<sup>27</sup>

The mechanisms by which low-dose oral MTX exerts its clinical effects are not fully understood. However, there is evidence of action on proinflammatory cytokines such as TNF- $\alpha$ , IL-1, IL-6 and immune-regulation pathways.<sup>28</sup>

Dermatologists and leprologists are familiar with using MTX, which is widely available and affordable in comparison to other agents used to manage ENL. There are reports, including a case series of MTX having a beneficial

effect in the management of ENL,<sup>29–31</sup> however, there are no controlled trials of MTX in ENL.

MTX may take up to 12 weeks for a therapeutic effect to be noticeable in psoriasis.<sup>24</sup> We hypothesise that MTX used in conjunction with prednisolone will improve the clinical outcomes for patients with ENL.

## METHODS AND ANALYSIS

### Definitions

ENL is defined as occurring when an individual with BL or LL leprosy develops 10 or more tender papular and/or nodular skin lesions.

Three clinical patterns of ENL are described: single acute episodes, recurrent episodes and chronic.<sup>1,3,20</sup>

Acute ENL is defined as occurring if a patient has either a first episode of ENL of less than 24 weeks duration or experiences a second or subsequent episode of ENL, which lasts less than 24 weeks and occurs 84 days (ie, 12 weeks) or more after stopping treatment for ENL.<sup>4</sup>

Chronic ENL is defined as occurring for more than 24 weeks during which a patient has required ENL treatment either continuously or where any treatment-free period is 27 days or less.<sup>4</sup>

Recurrent ENL is defined as occurring if a patient experienced a second or subsequent episode of ENL occurring between 28 and 84 days after stopping treatment for ENL.<sup>4</sup>

Erythema Nodosum Leprosum International Study (ENLIST) ENL severity scale (EESS) is a 10-item validated severity scale which will be used as an outcome measurement.

### Study design

MTX and prednisolone study in ENL (MaPs) is a multi-centre double-blind RCT with two treatment arms, to study the efficacy of MTX and prednisolone in ENL compared with prednisolone and placebo. Participants will be stratified by type of ENL (acute or chronic/recurrent). The procedures for both types will be the same, however, they will be analysed separately.

Specialist leprosy referral institutions from six countries will participate in this study: DBLM Hospital Nilphamari; The Leprosy Mission Bangladesh; Oswaldo Cruz Institute; Rio de Janeiro, Brazil; the ALERT Center, Addis Ababa, Ethiopia; The Leprosy Mission Trust India, New Delhi, India; Bombay Leprosy Project, Mumbai, India; Dr Soetomo Hospital, Surabaya, Indonesia and Anandaban Hospital; The Leprosy Mission Nepal, Nepal.

### Participants

Participants will be the patients with leprosy diagnosed with ENL between 18 and 60 years of age, who give informed consent (online supplemental appendix 1, page 47). Participants must have an ENLIST EESS of 9 or more. EESS is a 10-item clinical severity scale for ENL, which has been developed and validated by the ENLIST group.<sup>32</sup> The range of scores possible is 0–30 and a score

of 9 or more has been shown to be associated with more severe ENL. Participants must also have at least 10 cutaneous ENL lesions.

Patients with longstanding ENL of more than 4 years, pregnant and breastfeeding women, patients coinfecting with hepatitis B or C or HIV, tuberculosis, pulmonary fibrosis and individuals with contra-indications to MTX will be excluded. Male and female patients not willing to practise contraception for the duration of the study will be excluded (in view of the teratogenic potential of MTX). Inclusion and exclusion criteria are listed in online supplemental appendix 2.

## Outcomes

### ► Primary outcomes

The primary outcomes of interest are the proportion of individuals who have not required additional prednisolone during the first 24 weeks and the first 48 weeks. These measurements were chosen because the requirement for additional prednisolone is an objective marker of ENL relapse and treatment failure.

### ► Secondary outcomes

The secondary outcomes to be assessed by comparisons between treatment arms are as follows. (1) The proportion of individuals with adverse events (AEs), (2) the proportion of individuals who do not require prednisolone at 60 weeks, (3) the number of flares of ENL per individual requiring additional prednisolone up to 60 weeks, (4) the maximal severity of flares of ENL requiring additional prednisolone up to 60 weeks, (5) the change in EESS score from baseline to the first flare of ENL requiring additional prednisolone, (6) the proportion of individuals who have not required additional prednisolone in the 60 weeks of the trial. (7, 8 and 9) The changes in patient-reported health-related quality of life (HRQoL) at 24, 48 and 60 weeks.

Participants will be assessed clinically and with investigations including a full blood count, renal function and liver function tests. Validated local language versions of the Dermatology Life Quality Index and the 36-item Short Form Survey will be used to assess HRQoL.

## Randomisation and allocation concealment

Each drug pack is identified by a serial number and the contents determined by a process of block randomisation that ensures an equal number of active and placebo treatments within each block.

Drug packs are to be distributed to centres in a way that maintains the serial numbering, so there will be only minor differences in the number of active and placebo drug packs available in each centre. In each centre, the drug packs are to be distributed in order by serial number. The key will be held by the Principal Investigator (PI), study manager and local PI of each centre and will be broken after the data analysis is completed or earlier for patients with severe AEs as defined by the protocol.

## Sample size calculation

In participants with acute ENL, if MTX reduces recurrence requiring additional steroid treatment by 30% (ie, ENL recurs in 37% rather than 67% as in the published study by Kaur *et al*<sup>18</sup>) then for a 90% power with  $\alpha=0.05$ , the number of participants required in each arm of this RCT is 57. Assuming 20% loss to follow-up, we require 142 participants.

In participants with chronic or recurrent ENL, if the proportion of patients taking 50% less prednisolone by the end of the study is increased with MTX treatment by 20% (assuming that 40% of those in the MTX group will achieve this target and 20% taking prednisolone will achieve this target, that is, two times the proportion in the MTX arm) then for 90% power with  $\alpha=0.05$ , the number of participants required in each arm of this RCT is 109. Assuming 20% loss of follow-up, we would require 274 participants with chronic/recurrent ENL.


## Follow-up

Participants will be in the study for 60 weeks and will be reviewed on 20 occasions. Participants who miss follow-up appointments will be contacted by phone.

The overview of the study is shown in figure 1.

## Treatment arms

All participants in the intervention arm will receive an initial dose of oral MTX 10mg, which will be increased to 15mg the following week. Participants weighing less



**Figure 1** Overview of methotrexate and prednisolone study in erythema nodosum leprosum randomised controlled trial. MTX, methotrexate.

**Table 1** Treatment schedule for MaPs in ENL.

Time from enrolment	MTX +prednisolone group		Placebo +prednisolone group	
Week	Methotrexate (mg/week) (MTX tablets will be 2.5 mg)	Prednisolone (mg/day)	Prednisolone (mg/day)	Dummy methotrexate (number of tablets/week)
0	10	40	40	4
1–7	15	40	40	6
2	15	35	35	6
3	15	35	35	6
4	15	30	30	6
5	15	30	30	6
6	15	25	25	6
7	15	25	25	6
8	15/20	20	20	6/8
9	15/20	20	20	6/8
10	15/20	20	20	6/8
11	15/20	20	20	6/8
12	15/20	15	15	6/8
13	15/20	15	15	6/8
14	15/20	15	15	6/8
15	15/20	15	15	6/8
16	15/20	10	10	6/8
17	15/20	10	10	6/8
18	15/20	5	5	6/8
19	15/20	5	5	6/8
20–47	15/20	0	0	6/8
48	10	0	0	4
49	10	0	0	4
50	5	0	0	2
51	5	0	0	2
52–59	0	0	0	0

Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly and individuals weighing 60 kg or more will receive MTX 20 mg from week 8.

ENL, erythema nodosum leprosum; MaPs, methotrexate and prednisolone study; MTX, methotrexate.

than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing more than 60 kg will have the weekly dose of MTX increased to 20 mg from week 8.

At week 48, the MTX will be reduced to 10 mg for 2 weeks followed by 5 mg for 2 weeks and then stopped.

In the control arm, participants will receive an equivalent number of identical dummy tablets.

All trial participants will receive prednisolone for 20 weeks. The initial dose will be 40 mg/day, reducing to 0. The study medications received by participants are detailed in [table 1](#).

### Medication

All participants will be prescribed folic acid 5 mg/day to minimise MTX-related adverse effects.<sup>24</sup>

### Adverse event

All participants will be assessed for the occurrence of AEs of MTX and/or prednisolone using detailed clinical assessments and laboratory parameters.<sup>33</sup>

Nausea is a common AE of MTX, which may be severe enough to limit therapy and may lead to loss of concealment of group allocation in the study. Up to 35% of patients treated with MTX may experience nausea.<sup>34</sup> Folate supplementation can reduce nausea and prevent anaemia and it is recommended for patients taking MTX.<sup>24 35 36</sup> Gastrointestinal (GI) AEs associated with corticosteroids are common in ENL trials. In a study in Ethiopia of 33 participants with ENL, 57% reported GI AEs.<sup>20</sup> An Indian RCT reported 43% of participants



experienced GIAEs.<sup>18</sup> ENL is a chronic condition, therefore many study trial participants have a long history of corticosteroid use. However, even in treatment of individuals newly diagnosed with leprosy reactions, GI AEs are common. In a nerve function impairment (NFI) prophylaxis study, almost 20% of participants who received prednisolone experienced GI symptoms.<sup>37</sup>

In the event of a serious AE, the allocation will be unmasked and an individualised treatment scheme initiated. In the event of a minor AE, additional medication will be prescribed according to the standard of care, but allocation will not be unmasked.

### Indications for additional corticosteroids

The indications for additional prednisolone are defined in the protocol as:

1. Flare or deterioration in ENL characterised by ENL symptoms and/or signs resulting in an increased EESS score to 9 or more; an increase in EESS score of 5 or more; orchitis not responding to conservative management and iritis not responding to topical steroids/mydriatics.
2. New or a deterioration in nerve function impairment (NFI) characterised by motor impairment or sensory impairment.
3. Type 1 leprosy reaction.

Any participant needing additional prednisolone will receive a reducing course of prednisolone as per protocol (see online supplemental appendix 1, page 33).

### Monitoring

During the study period, the study manager will monitor data collection. Meetings to update the progress of the study and identify any issue will be scheduled according to each centre's needs and if necessary further training can be provided to address problems arising. Regular online meetings will be conducted with all centres to discuss issues and updates.

### Data safety monitoring board

A data safety monitoring board (DSMB) has been established with independent researchers with access to unblinded data to review the accruing data, to monitor the progress of the study, to assess whether there are any safety issues and to advise the sponsor whether to continue, modify or stop the trial. The DAMOCLES (Data Monitoring Committees: Lessons, Ethics, Statistics) charter was used as the model for organisation of the DSMB.<sup>38</sup>

### Data collection

Data will be collected and managed using REDCap electronic data capture tools hosted at London School of Hygiene & Tropical Medicine.<sup>39</sup> REDCap is a secure, web-based application designed to support data capture for research studies providing audit trails for tracking data manipulation and export procedures; automated export procedures for seamless data downloads to common statistical packages and procedures for importing data from

external sources. Identifiable data will not be exported to the database but will be kept at each centre.

### Data analysis

The primary objective of the statistical analyses is to evaluate the efficacy and safety of MTX in the treatment of adult participants with acute and chronic/recurrent ENL. The efficacy analysis will be conducted in the intent-to-treat population, safety analysis will be conducted in the safety population. The analyses for the primary outcomes for both parts of the trial each require a straightforward comparison of percentages. In addition, we will carry out last observation carry-forward (LOCF) analyses. This will mean that all subjects who are randomised will be analysed. However, we are aware of the limitations of the LOCF approach and will also apply the likelihood-based method of mixed-effect model repeated measures (MMRM).<sup>40</sup> We will also complete per protocol analyses. For secondary outcomes, LOCF and MMRM analyses will be applied.

Data and all appropriate documentation will be stored for a minimum of 5 years after the completion of the study, including the follow-up period.

### Patient and public involvement

Individuals affected by ENL were consulted about the need for improved treatments and willingness to participate in clinical studies.

### Ethics and dissemination

Ethical approval was obtained from the Observational/Interventions Research Ethics Committee of the London School of Hygiene & Tropical Medicine (15762); The Leprosy Mission International Bangladesh Institutional Research Board (in process); AHRI-ALERT Ethical Review Committee; Ethics Committee of the Managing Committee of the Bombay Leprosy Project; Health Research Ethics Committee Dr. Soetomo; The Leprosy Mission Trust India Ethics Committee; the Nepal Health and Research Council.

This study is registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Results will be submitted for publication in peer-reviewed journals and conclusions from the work will be presented at each participating centre and shared with study participants and other stakeholders. This article is based on the third version of the study protocol reviewed on 20 November 2018 (online supplemental appendix 1).

### DISCUSSION

MaPs is a multicentre double-blind RCT, which aims to assess the efficacy of oral MTX in ENL. Corticosteroids are the most widely used drugs for the management of ENL. The use of prednisolone and other corticosteroids leads to severe complications such as infections, peptic ulcer, osteoporosis, glaucoma, diabetes and hypertension. Long-term use of these medications is associated with morbidity and mortality. Moreover, many patients



suffer recurrent ENL when the dose of prednisolone is reduced.<sup>1</sup> MTX has been used successfully in patients unresponsive to thalidomide and corticosteroids, making it an ideal candidate as a corticosteroid-sparing agent.

MaPs in ENL will be the first randomised clinical trial evaluating MTX as an option for ENL treatment. It will be the first ENL RCT to use the EESS tool to assess the severity and response to treatment, which will represent a major development in evidence-based therapeutics for ENL. We have developed criteria to standardise the prescribing of additional corticosteroids that could be used in other clinical trials of ENL.

MaPs in ENL will contribute to the evidence for the treatment of ENL and improve clinical trial methodology in leprosy reactions. Importantly, MaPs in ENL will use patients' reported outcome measures, which are valuable tools to assess outcomes. MTX if efficacious and safe will be an affordable and accessible medication with the potential to improve outcomes for individuals with this severe complication of leprosy.

#### Author affiliations

<sup>1</sup>Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK

<sup>2</sup>Clinical Research Department, ALERT Center, Addis Ababa, London, Ethiopia

<sup>3</sup>Department of Dermatology and Mycobacterial Research Laboratories, The Leprosy Mission Nepal, Anandaban Hospital, Kathmandu, Nepal

<sup>4</sup>Bombay Leprosy Project, Mumbai, India

<sup>5</sup>The Leprosy Mission Trust India, New Delhi, Indonesia

<sup>6</sup>DBLM Hospital, The Leprosy Mission International Bangladesh, Nilphamari, Bangladesh

<sup>7</sup>Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga, Dr Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia

<sup>8</sup>Leprosy Laboratory, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

**Contributors** Conceptualisation: SLW, DL. Data curation: PGN. Formal analysis: BdB, SLW, PGN. Study manager: BdB. Funding acquisition: SLW, DL. Investigation: MDA, CRB, JD, BdB, SD, DAH, SML, DL, NM, JACN, KDN, PGN, VVP, BJR, AMS, MS, DS, SLW, AMY, VLAD. Methodology: MDA, CRB, JD, BdB, SD, DAH, SML, MYL, DL, JACN, KDN, PGN, VVP, BJR, AS, MS, DS, SLW, AMY. Project administration: MDA, CRB, JD, BdB, SD, DAH, SML, DL, NM, JACN, KDN, PGN, VVP, BJR, AS, MS, DS, SLW. Writing – original draft: BdB, SLW. Writing – review & editing: MDA, CRB, JD, SD, DAH, SML, DL, NM, JACN, KDN, PGN, VVP, BJR, AS, MS, DS, SLW.

**Funding** This work is supported by Leprosy Research Initiative, Turing Foundation and plan:g under LRI grant number 704.16.71 and The Hospital and Homes of St. Giles, grant number ITCRZM25.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Barbara de Barros <http://orcid.org/0000-0002-5382-8165>

Saba M Lambert <http://orcid.org/0000-0003-4376-5495>

Stephen L Walker <http://orcid.org/0000-0002-2034-8376>

#### REFERENCES

- Pocaterra L, Jain S, Reddy R, *et al*. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. *Am J Trop Med Hyg* 2006;74:868–79.
- Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. *Int J Lepr Other Mycobact Dis* 2004;72:125.
- Walker SL, Lebas E, Doni SN, *et al*. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. *PLoS Negl Trop Dis* 2014;8:e2690.
- Walker SL, Balagon M, Darlong J, *et al*. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. *PLoS Negl Trop Dis* 2015;9:e0004065.
- Chandler DJ, Hansen KS, Mahato B, *et al*. Household costs of leprosy reactions (ENL) in rural India. *PLoS Negl Trop Dis* 2015;9:e0003431–13.
- Job CK, Ebenezer GJ, Thompson K, *et al*. Pathology of eye in leprosy. In: *Indian Journal of Leprosy*. Vol 1998;70:79–91.
- Polycarpou A, Walker SL, Lockwood DNJ. A systematic review of immunological studies of erythema nodosum leprosum. *Front Immunol* 2017;8:233.
- Moraes MO, Sarno EN, Almeida AS, *et al*. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (Rr and ENL). *Scand J Immunol* 1999;50:541–9.
- Narayanan RB, Laal S, Sharma AK, *et al*. Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. *Clin Exp Immunol* 1984;55:623–8 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1535912&tool=pmcentrez&rendertype=abstract>
- Sarno EN, Grau GE, Vieira LM, *et al*. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. *Clin Exp Immunol* 1991;84:103–8.
- Walker SL, Waters MFR, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. *Lepr Rev* 2007;78:197–215 <http://www.ncbi.nlm.nih.gov/pubmed/18035771>
- Nabarro LEB, Aggarwal D, Armstrong M, *et al*. The use of steroids and thalidomide in the management of erythema nodosum leprosum: 17 years at the hospital for tropical diseases, London. *Lepr Rev* 2016;87:221–31.
- Mahmoud M, Walker SL. A systematic review of adverse drug reactions associated with thalidomide in the treatment of erythema nodosum leprosum. *Lepr Rev* 2019;90:142–60.
- Van Veen NHJ, Lockwood DNJ, Van Brakel WH, *et al*. Interventions for erythema nodosum leprosum. A cochrane review. *Lepr Rev* 2009;80:355–72.
- Girdhar A, Chakma JK, Girdhar BK. Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study. *Indian J Lepr* 2002;74:233–6.
- Villahermosa LG, Fajardo TT, Abalos RM, *et al*. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. *Am J Trop Med Hyg* 2005;72:518–26.
- Sales AM, de Matos HJ, Nery JAC, *et al*. Double-Blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. *Braz J Med Biol Res* 2007;40:243–8.
- Kaur I, Dogra S, Narang T, *et al*. Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. *Australas J Dermatol* 2009;50:181–5.
- Roy K, Sil A, Das NK, *et al*. Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study. *Int J Dermatol* 2015;54:1325–32.
- Lambert SM, Nigusse SD, Alembo DT, *et al*. Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: two randomised, double blind, controlled pilot studies in Ethiopia. *PLoS Negl Trop Dis* 2016;10:e0004149.
- Kar HK, Gupta L. Comparative efficacy of four treatment regimens in type 2 leprosy reactions (prednisolone alone, thalidomide alone,

- prednisolone plus thalidomide and prednisolone plus clofazimine). *Indian J Lepr* 2016;88:29–38.
- 22 Maghanoy A, Balagon M, Saunderson P, *et al*. A prospective randomised, double-blind, placebo controlled trial on the effect of extended clofazimine on erythema nodosum leprosum (ENL) in multibacillary (MB) leprosy. *Lepr Rev* 2017;88:208–16.
  - 23 Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. *Pharmacol Reports* 2006;58:473–92.
  - 24 Warren RB, Weatherhead SC, Smith CH, *et al*. British association of dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. *Br J Dermatol* 2016;175:23–44.
  - 25 Gubner R. Effect of "aminopterin" on epithelial tissues. *A M A Arch Dermatology Syphilol* 1951.
  - 26 Hashkes PJ, Becker ML, Cabral DA, *et al*. Methotrexate: new uses for an old drug. *J Pediatr* 2014;164:231–6.
  - 27 WHO. World Health organization model list of essential medicines. *Who/mvp/emp/iau* 2019;6.
  - 28 Bedoui Y, Guillot X, Sélambarom J, *et al*. Methotrexate an old drug with new tricks. *Int J Mol Sci* 2019;20. doi:10.3390/ijms20205023. [Epub ahead of print: 10 Oct 2019].
  - 29 Hossain D, Delwar H. Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. *Lepr Rev* 2013;84:105–12.
  - 30 Kar BR, Babu R. Methotrexate in resistant ENL. *Int J Lepr Other Mycobact Dis* 2004;72:480.
  - 31 Rahul N, Sanjay KS, Singh S. Effectiveness of methotrexate in prednisolone and thalidomide resistant cases of type 2 lepra reaction: report on three cases. *Lepr Rev* 2015;86:379–82 <http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=112006561&lang=es&site=ehost-live>
  - 32 Walker SL, Sales AM, Butlin CR, *et al*. A leprosy clinical severity scale for erythema nodosum leprosum: an international, multicentre validation study of the ENLIST ENL severity scale. *PLoS Negl Trop Dis* 2017;11:e0005716–14.
  - 33 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356:1255–9.
  - 34 Kingsley GH, Kowalczyk A, Taylor H, *et al*. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. *Rheumatology* 2012;51:1368–77.
  - 35 Lorenzi AR, Johnson AH, Gough A. Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription. *Rheumatology* 2000;39:812–3.
  - 36 Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J Am Acad Dermatol* 1993;28:466–9.
  - 37 Smith WCS, Anderson AM, Withington SG, *et al*. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). *BMJ* 2004;328:1459–62.
  - 38 DAMOCLES Study Group, NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. *Lancet* 2005;365:711–22.
  - 39 Harris PA, Taylor R, Thielke R, *et al*. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.
  - 40 Siddiqui O, Hung HMJ, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. *J Biopharm Stat* 2009;19:227–46.